Type 1 diabetes mellitus (T1DM) is identified in this guidance as a chronic autoimmune disorder characterized by progressive immune-mediated destruction of pancreatic beta cells. Historically managed primarily with insulin replacement, advances in disease staging and early detection are enabling a shift toward interventions that modify disease course. This guidance statement was jointly developed by adult and pediatric endocrinology experts, including the Endocrinology, Genetics and Metabolism Group of the Society of Pediatrics, the Adolescent Health and Medicine Committee of the Chinese Medical Doctor Association, and the National Clinical Research Center for Metabolic Diseases (Changsha). Its stated purpose is to provide clinicians with standardized, evidence-informed references for the clinical application of disease-modifying therapies (DMTs) and immunotherapy in T1DM to support more precise care and improved outcomes.
The guidance reviews the immune pathogenesis underlying T1DM, emphasizing that progressive autoimmune activity leads to gradual loss of insulin-producing beta cells. It adopts the established three-stage classification for T1DM, a framework that segments disease progression from at-risk or presymptomatic immune activation through to clinical onset. The three-stage model underpins the rationale for earlier intervention: identifying and treating individuals before overt hyperglycemia may preserve residual beta-cell function and alter long-term disease trajectory.
The guidance highlights the role of expanded early screening programs to detect individuals in presymptomatic or early stages of T1DM. Early identification of at-risk persons enables consideration of immunotherapy or other DMTs at a time when interventions may be more effective. The guidance is intended for clinical endocrinologists involved in diagnosis and management of T1DM and emphasizes a multidisciplinary approach spanning pediatric and adult care. Specific screening modalities, thresholds, and population-level screening protocols were discussed in the full text; details beyond the abstract are available in the full article.
The document systematically describes the mechanisms of action and development progress for five categories of immunotherapeutic agents relevant to T1DM. While the abstract does not enumerate these five categories or provide granular comparative data, the guidance frames these agents collectively as representatives of DMT strategies that aim to intervene in immune processes rather than merely replace insulin function. The overview is intended to orient clinicians to the therapeutic classes, their mechanistic rationale, and the state of clinical development as of 2026.
Among specific therapies, the guidance provides detailed recommendations for the clinical application of teplizumab in patients with stage 2 T1DM. The guidance addresses: eligible patient populations, recommended pre-treatment assessments, and considerations for selecting candidates for therapy. The abstract indicates that teplizumab guidance covers treatment initiation criteria in stage 2 disease, but the abstract does not list the explicit eligibility criteria or the exact components of the pre-treatment workup; those particulars are presented in the full text of the guidance.
The statement elaborates on dosing regimens, strategies for recognizing and managing anticipated adverse events, and follow-up approaches for patients receiving teplizumab. The guidance therefore seeks to provide clinicians with practical operational recommendations for safe administration and monitoring. The abstract summarizes that dosing, adverse event management, and follow-up strategies are covered in detail for teplizumab; however, the abstract does not include the specific dosing schedules, safety algorithms, or monitoring intervals. Clinicians should consult the full text for the explicit protocols and operational steps.
A central aim of this guidance is to support standardized clinical application of DMTs and immunotherapy in routine practice, enabling more precise, individualized treatment decisions for patients with T1DM. By outlining pathogenesis, staging, therapeutic categories, and a practical framework for teplizumab use in stage 2 disease, the guidance promotes integration of etiologic interventions into clinical workflows previously dominated by insulin replacement. The document targets clinical endocrinologists and multidisciplinary teams engaged in the care of both pediatric and adult patients.
The article reports that all authors declare no conflicts of interest. The guidance was published in Zhonghua Yi Xue Za Zhi (2026 Sep 29;106(36):3832-3845) and is available in Chinese with an English abstract on PubMed (PMID: 42778314; DOI: 10.3760/cma.j.cn112137-20260617-01569). Full text access is provided through the Chinese Medical Association Publishing House linkout noted on PubMed.
Notes on source limitations
All statements above reflect the content summarized in the PubMed record and abstract. The PubMed abstract indicates that the full guidance includes detailed operational recommendations; where the abstract did not provide explicit numeric dosing regimens, specific eligibility thresholds, or stepwise adverse event algorithms, this summary refrains from inventing those details. Clinicians should consult the full guidance document for exact protocols, dosing schedules, laboratory and imaging requirements for pre-treatment assessment, and precise monitoring recommendations.